Literature DB >> 29384980

Infectious Diseases Consultation Improves Treatment and Decreases Mortality by Enterococcal Bacteremia in Children.

Munehiro Furuichi1, Mihoko Furuichi2, Yuho Horikoshi2, Isao Miyairi1,3.   

Abstract

BACKGROUND: Enterococci can cause severe infectious diseases (IDs). Delaying appropriate antibiotic therapy for enterococcal bacteremia is associated with increased patient mortality.
METHODS: We conducted a retrospective analysis examining the characteristics of children with enterococcal bacteremia at the 2 largest children's hospitals in Japan. We compared outcomes of enterococcal bacteremia patients who received IDs consultation with those who did not. We also evaluated the risk factors for 30-day mortality after onset of enterococcal bacteremia.
RESULTS: One hundred fifty-two episodes of enterococcal bacteremia developed in 142 children. The most common pathogen was Enterococcus faecalis (94 episodes, 62%) followed by E. faecium (46 episodes, 30%). An underlying disease was present in 146 (96%) episodes. The most common type of infection was catheter-related blood stream infection (90, 59%). ID consultation, provided in 100 of 152 episodes of enterococcal bacteremia, was significantly associated with a higher rate of appropriate empiric therapy (84% versus 56%; P < 0.001) and appropriate definitive therapy (98% versus 73%; P < 0.001), treatment duration ≥7 days (97% versus 78%; P < 0.001), and the survival rate during 1 year postonset (P = 0.047). Seventeen children died within 30 days of enterococcal bacteremia onset. In multivariate analysis, those who received definitive therapy with penicillin without glycopeptides were at a statistically lower risk for death within 30 days after onset of enterococcal bacteremia (OR: 0.12; 95% confidence interval: 0.02-0.70; P = 0.02).
CONCLUSIONS: ID consultation was associated with a higher rate of appropriate therapy and may decrease mortality because of enterococcal bacteremia in children.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29384980     DOI: 10.1097/INF.0000000000001919

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  6 in total

1.  Increasing Pediatric Infectious Diseases Consultation Rates for Staphylococcus aureus Bacteremia.

Authors:  Oren Gordon; Nadine Peart Akindele; Christina Schumacher; Ann Hanlon; Patricia J Simner; Karen C Carroll; Anna C Sick-Samuels
Journal:  Pediatr Qual Saf       Date:  2022-06-14

Review 2.  Infectious disease specialist consultations in a Japanese cancer center: a retrospective review of 776 cases.

Authors:  Naoya Itoh; Yoshiro Hadano; Yasumasa Yamamoto; Norihiko Terada; Hanako Kurai
Journal:  BMC Health Serv Res       Date:  2020-06-03       Impact factor: 2.655

3.  Understanding and Application of Daptomycin-Susceptible Dose-Dependent Category for Enterococcus: A Mixed-Methods Study.

Authors:  Jennifer L Adema; Laurel N Lake; Ryan W Stevens; Breann M Hogan; Audrey N Schuetz; Aaron J Tande; Kristin C Mara; Allison R Eberly; Christina G Rivera
Journal:  Open Forum Infect Dis       Date:  2022-01-10       Impact factor: 3.835

4.  Impact of Infectious Diseases Consultation on the Outcome of Patients With Enterococcal Bacteremia: A Systematic Literature Review and Meta-analysis.

Authors:  Joseph Tholany; Takaaki Kobayashi; Alexandre R Marra; Marin L Schweizer; Riley J Samuelson; Hiroyuki Suzuki
Journal:  Open Forum Infect Dis       Date:  2022-04-12       Impact factor: 4.423

5.  The impact of infectious diseases consultation on the management and outcomes of Pseudomonas aeruginosa bacteraemia in adults: a retrospective cohort study.

Authors:  Fabian Chiong; Mohammed S Wasef; Kwee Chin Liew; Raquel Cowan; Danny Tsai; Yin Peng Lee; Larry Croft; Owen Harris; Stella May Gwini; Eugene Athan
Journal:  BMC Infect Dis       Date:  2021-07-09       Impact factor: 3.090

6.  Infectious Diseases Consultation Is Associated With Decreased Mortality in Enterococcal Bloodstream Infections.

Authors:  Rachael A Lee; Daniel T Vo; Joanna C Zurko; Russell L Griffin; J Martin Rodriguez; Bernard C Camins
Journal:  Open Forum Infect Dis       Date:  2020-02-19       Impact factor: 3.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.